Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Gatorade Sports and Science Institute | OTHER |
| Quercegen Pharmaceuticals | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether dietary quercetin supplementation effects thermotolerance and heat acclimation in human subjects exposed to exercise/heat stress.
Specific Aim I. To determine if quercetin in combination with repeated bouts of thermally stressful exercise will impact intestinal barrier function. The investigators will examine urinary lactulose excretion, plasma endotoxin,plasma quercetin, inflammatory cytokines (TNF-a & Il-6), anti-inflammatory cytokines (Il-10), and HSP70 and HSF-1 content of peripheral blood mononuclear cells.
Specific Aim II. To determine whether quercetin's suppresses the ability of human subjects to acclimate to exercise/heat stress. The investigators will examine body temperatures, heart rates, physiological strain, sweat and plasma volume responses to standardized heat tolerance tests.
Overall Protocol:
This study will involve a repeated-measures design (2 conditions) in which subjects will perform exercise in the heat. Each condition will begin with an Intestinal Permeability Measurement (IP1), where subjects will be admitted to the General Clinical Research Center (GCRC), drinking a test solution and collecting their urine for 8 hours to measure intestinal integrity prior to heat stress. This will be followed by a Heat Tolerance Trial (HT1: 50min exercise at 50% VO2max in environmental chamber controlled at 56oC, 20%RF), used as a baseline measurement of subject's capacity to work in the heat. Following HT1 each subject will perform 7 Days of Heat Acclimation (HA)exercise (controlled hyperthermia design, each subject will elevate core temperature >39oC in 50min during 50 minutes of exercise in environmental chamber controlled at 56oC, 20%RF; rest 10 min in environmental chamber; then perform another 50min of exercise at this elevated core temperature). On days 1 and 7 of HA subjects will follow exercise by performing additional Intestinal Permeability Measurements, providing pre (IP2) and post acclimation (IP3) measurements of intestinal permeability. Day 6 of HA will provide a posttest measurement of subjects' capacity to work in the heat, and will be synonymous with Heat Tolerance Trial 2 (HT2).
Subjects will take quercetin during the seven days of HA in one condition, and placebo in the other. At least 1 month must elapse before a subject will be allowed to repeat the opposite condition. The order will be balanced (half will take quercetin first, the other half placebo). This will be a double blinded study. Neither the investigators nor the subjects will know whether a HA involves quercetin or placebo.
Due to the possibility of outside factors causing variations in intestinal permeability over the course of the study, IP1 will always be used as a baseline condition, with IP2 and IP3 being scored relative (as percent change) to the first. Subjects will never be supplemented in IP1, as this might affect basal measurements of permeability. However, because quercetin supplementation may only exert a transient effect on intestinal permeability, subjects will always be supplemented (with either placebo or quercetin, according to condition) in IP2 and IP3.
In all conditions, subjects will be required to follow guidelines on diet and exercise. They will be instructed to avoid caffeine, alcohol, and to stay well hydrated. They will be instructed to avoid exercise that is not directly outlined by the experiment (see attached). Their meals will be provided by the GCRC to ensure adequate nutrition and to avoid high dietary levels of quercetin. We are currently working with BioNutrition on this menu. To ensure compliance with this diet, subjects will fill out a food diary.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Quercetin | Experimental | not necessary, contained in protocol |
|
| Placebo | Placebo Comparator | not necessary, contained in protocol |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quercetin | Dietary Supplement | 2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm |
|
| Measure | Description | Time Frame |
|---|---|---|
| Urinary Lactulose Excretion | Lactulose is a large molecule (disaccharide: 242 kDa) that should not be permeable to the gastrointestinal barrier under normal conditions. Subjects will ingest a test solution containing 10 g lactulose (Quintron Instrument Company, QT02500-10-5, Milwaukee, WI, USA) dissolved in 50 ml of distilled water. This is followed by 8 hour urine collection. | Baseline |
| Plasma endotoxin | Plasma endotoxin will be detected with a standard limulus amebocyte lysate (LAL) kit (Cell Sciences, HIT302, Canton, MA, USA). The minimum and maximum detection limits of this kit are 1.4 pg/ml and 1,000 pg/ml, respectively. | Baseline |
| Plasma Quercetin | Quercetin conjugates are hydrolysized from plasma with B-glucuronidase and arylsulfatase kit (Roche Diagnostics, 10127698001, Indianapolis, IN, USA). The resulting supernatant is applied to solid phase extraction cartridges and run through a vacuum manifold for purification. The eluent is 80% methanol / 20% 18 MOhm water. Following solid phase extraction chromatographic analysis is performed using high performance liquid chromatography (HPLC). | Baseline |
| Plasma TNF-a | pre, post, 2hours post, 4 hours post exercise on Day 1 of exercise/heat stress | |
| plasma Il-6 | Pre, post, 2hours post, 4 hours post exercise, day 1 of exercise/heat stress | |
| Plasma Il-10 | Pre, post, 2 hours post, 4 hours post exercise on Day 1 of exercise/heat stress | |
| HSP70 content of peripheral blood mononuclear cells |
| Measure | Description | Time Frame |
|---|---|---|
| Improvements in sweat rate following heat acclimation exercise | heat tolerance test 1= before study onset | |
| Plasma volume expansion in response to heat acclimation exercise | heat tolerance test 1= before study onset |
Not provided
Inclusion Criteria:
Healthy: 1 or less CV risk factor. Positive risk factors include:
Male
18-39 years of age
Willing to follow study diet
Willing to exercise for prescribed time
Willing to tolerate hot environment
Willing to avoid external influences (ambient heat, uv exposure, external exercise) for study duration
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pope L Moseley, MD | University of New Mexico, Professor and Chariman, Dpt of Internal Medicine | Principal Investigator |
| Matthew R. Kuennen, PhD | UNM Department of Health, Exercise and Sports Sciences and UNM Department of Internal Medicine | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UNM General Clinical Research Center | Albuquerque | New Mexico | 87131 | United States |
Not provided
| ID | Term |
|---|---|
| D018882 | Heat Stress Disorders |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D011794 | Quercetin |
| ID | Term |
|---|---|
| D044948 | Flavonols |
| D005419 | Flavonoids |
| D002867 | Chromones |
| D001578 | Benzopyrans |
| D011714 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions |
|
| Pre, post, 2 hours post, 4 hours post exercise on day 1 of exercise/heat stress |
| HSF-1 content of peripheral blood mononuclear cells | Pre, post, 2 hours post, 4 hours post exercise on day 1 of exercise/heat stress |
| Core temperature response to heat tolerance test | heat tolerance test 1= before study onset |
| Skin temperature response to heat tolerance test | heat tolerance test 1= before study onset |
| Mean body temperature response to heat tolerance test | heat tolerance test 1= before study onset |
| Heart rate response to heat tolerance test | heat tolerance test 1= before study onset |
| Physiological strain response to heat tolerance test | heat tolerance test 1= before study onset |
| Urinary Lactulose Excretion | Day 1 of exercise/heat stress |
| Urinary Lactulose Excretion | Day 7 of exercise/heat stress |
| Plasma Quercetin | Day 1 of exercise/heat stress |
| Plasma Quercetin | Day 7 of exercise/heat stress |
| Plasma Endotoxin | Day 1 of exercise/heat stress |
| plasma endotoxin | day 7 of exercise/heat stress |
| Plasma TNF-a | pre, post, 2hours post, 4 hours post exercise on Day 7 of exercise/heat stress |
| plasma Il-10 | pre, post, 2hours post, 4 hours post exercise on Day 7 of exercise/heat stress |
| plasma Il-6 | pre, post, 2hours post, 4 hours post exercise on Day 7 of exercise/heat stress |
| HSP70 content of peripheral blood mononuclear cells | pre, post, 2hours post, 4 hours post exercise on Day 7 of exercise/heat stress |
| HSF-1 content of peripheral blood mononuclear cells | pre, post, 2hours post, 4 hours post exercise on Day 7 of exercise/heat stress |
| Core temperature response to heat tolerance test | heat tolerance trial 2 = day 6 of exercise/heat stress |
| Skin temperature response to heat tolerance test | heat tolerance trial 2 = day 6 of exercise/heat stress |
| Mean body temperature response to heat tolerance test | heat tolerance trial 2 = day 6 of exercise/heat stress |
| Heart rate response to heat tolerance test | heat tolerance trial 2 = day 6 of exercise/heat stress |
| physiological strain response to heat tolerance test | heat tolerance trial 2 = day 6 of exercise/heat stress |
| Improvements in sweat rate following heat acclimation exercise | heat tolerance trial 2 = day 6 of exercise/heat stress |
| plasma volume expansion in response to heat acclimation exercise | heat tolerance trial 2 = day 6 of exercise/heat stress |
| Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |